INTANGIBLE ASSETS, NET - Narrative (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Indefinite-lived Intangible Assets [Line Items] | ||||
| Impairment charge | $ 0 | $ 19,000,000 | ||
| Deferred tax liability, write-off | 0 | 6,650,000 | ||
| Amortization of intangible assets | 701,000 | 763,000 | ||
| Finite-lived intangible assets, impairment charge | $ 0 | 0 | ||
| Herbal Brands, Inc | ||||
| Indefinite-lived Intangible Assets [Line Items] | ||||
| Finite-lived intangible assets acquired | $ 7,091,000 | |||
| Licensing Agreements | ||||
| Indefinite-lived Intangible Assets [Line Items] | ||||
| Indefinite-lived intangible assets acquired | $ 19,000,000 | |||
| Impairment charge | $ 19,000,000 | |||
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|